Search
 

23andMe case signals stricter oversight of genetic testing

The change could have widespread implications for people who may be interested in information about their genetic makeup.

By Scott Wooldridge | Updated on January 02, 2014

A move by the Food and Drug Administration that effectively shut down marketing of health data in a genetic test aimed at consumers may be part of a wider move to increase regulation of the industry.

The change could have widespread implications, both for people who may be interested in information about their genetic makeup and for health care professionals who are increasingly using high-tech diagnostics to fight disease. A 2012 report by UnitedHealth Group found that the U.S. is currently spending more than $5 billion annually on genetic testing, and that number may increase to $25 billion by 2021.

Complete your profile to continue reading and get FREE access to BenefitsPRO.com, part of your ALM digital membership.

Your access to unlimited BenefitsPRO.com content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical BenefitsPRO.com information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com

Already have an account?

Dig Deeper

 

Recommended Stories

BenefitsPRO

Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2023 ALM Global, LLC. All Rights Reserved.